D
Darrel P. Cohen
Researcher at Pfizer
Publications - 21
Citations - 2352
Darrel P. Cohen is an academic researcher from Pfizer. The author has contributed to research in topics: Sunitinib & Imatinib mesylate. The author has an hindex of 12, co-authored 21 publications receiving 2163 citations. Previous affiliations of Darrel P. Cohen include Duke University & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael Heinrich,Robert G. Maki,Christopher L. Corless,Cristina R. Antonescu,Amy Harlow,Diana J. Griffith,Ajia Town,Arin McKinley,Wen-Bin Ou,Jonathan A. Fletcher,Christopher D.M. Fletcher,Xin Huang,Darrel P. Cohen,Charles M. Baum,George D. Demetri +14 more
TL;DR: The clinical activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases, which has implications for optimization of the treatment of patients with GIST.
Journal ArticleDOI
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini,Darrel P. Cohen,Dongrui R. Lu,Isan Chen,Subramanian Hariharan,Martin Gore,Robert A. Figlin,Michael S. Baum,Robert J. Motzer +8 more
TL;DR: In patients with metastatic renal cell carcinoma, sunitinib-associated HTN is associated with improved clinical outcomes without clinically significant increases in HTN-associated adverse events, supporting its viability as an efficacy biomarker.
Journal ArticleDOI
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
Suzanne George,J.-Y. Blay,Paolo G. Casali,A. Le Cesne,P. Stephenson,Samuel E. DePrimo,Charles S. Harmon,C.N.J. Law,Jeffrey A. Morgan,Isabelle Ray-Coquard,V. Tassell,Darrel P. Cohen,George D. Demetri +12 more
TL;DR: For patients with imatinib-resistant/intolerant GIST, continuous daily sunitinib dosing appears to be an active alternative dosing strategy with acceptable safety.
Journal ArticleDOI
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
Sai-Hong Ignatius Ou,Pasi A. Jänne,Cynthia Huang Bartlett,Yiyun Tang,Dong Wan Kim,Gregory A. Otterson,L. Crinò,Paulina Selaru,Darrel P. Cohen,Jeffrey W. Clark,Gregory J. Riely +10 more
TL;DR: Continuing ALK inhibition with crizotinib after PD may provide survival benefit to patients with advanced ALK-positive NSCLC and patients who continued CBPD were more likely to have good ECOG PS at the time of PD.
Journal ArticleDOI
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
George D. Demetri,Michael Heinrich,Jonathan A. Fletcher,Christopher D.M. Fletcher,Annick D. Van den Abbeele,Christopher L. Corless,Cristina R. Antonescu,Suzanne George,Jeffrey A. Morgan,Ming-Hui Chen,Carlo L. Bello,Xin Huang,Darrel P. Cohen,Charles M. Baum,Robert G. Maki +14 more
TL;DR: Cellular and molecular analyses showed that sunitinib clinical activity is associated with inhibition of KIT in GIST following imatinib failure, illustrating the rational approach used to develop a therapy aimed at the underlying oncogenic signaling pathway aberrancy.